Key result
First-year intimal thickness progression ≥0.5 mm linked to ~3.5-fold higher post-transplant death or graft loss.
Why the study?
Cardiac allograft vasculopathy is a major impediment to long-term graft survival, and the validity of first-year IVUS data as a surrogate marker for long-term outcome after heart transplantation was uncertain.
Does first-year progression of intimal thickness >=0.5 mm on IVUS predict long-term mortality and adverse events in heart transplant recipients?
Cohort (n=125)
Yes
Does first-year progression of intimal thickness >=0.5 mm on IVUS predict long-term mortality and adverse events in heart transplant recipients?
Answers are grounded in this paper and cite their sources.
First-year progression of intimal thickening >=0.5 mm on IVUS is a reliable surrogate marker for 5-year mortality and adverse cardiac events after heart transplantation.
OBJECTIVES: We sought to assess the validity of first-year intravascular ultrasound (IVUS) data as a surrogate marker for long-term outcome after heart transplantation. BACKGROUND: Cardiac allograft vasculopathy (CAV) is a major impediment to long-term graft survival. Intravascular ultrasound is more sensitive than coronary angiography and detects intimal thickening (early CAV) in the coronary arteries of the donor heart. Single-center studies have suggested first-year IVUS results might be a surrogate marker for long-term outcome. METHODS: First-year IVUS results and subsequent five-year clinical follow-up data were reviewed in 125 heart transplant recipients from five institutions. The IVUS tapes (at baseline and one year) were re-analyzed at a core IVUS laboratory. The change in maximal intimal thickness (MIT) from baseline to one year was recorded for several matched sites in the same coronary artery. Patients were classified into two groups: those with >/=0.5 mm in the MIT in any matched site (group 1) and those with MIT <0.5 mm (group 2). RESULTS: Group 1 patients compared with group 2 patients had a higher incidence of death or graft loss (D/GL, 20.8% vs. 5.9%; p = 0.007), had more nonfatal major adverse cardiac events and/or D/GL (45.8% vs. 16.8%; p = 0.003), and had more findings of newly occurring angiographic luminal irregularities (65.2% vs. 32.6%, p = 0.004). CONCLUSIONS: This multicenter study suggests that progression of intimal thickening >/=0.5 mm in the first year after transplantation appears to be a reliable surrogate marker for subsequent mortality, nonfatal major adverse cardiac events, and development of angiographic CAV through five years after heart transplantation.
No takes yet. Share an insight, caveat, or question.
Kobashigawa et al. (2005) conducted a cohort in Heart transplant recipients (n=125). Progression of maximal intimal thickness ≥0.5 mm vs. Maximal intimal thickness <0.5 mm was evaluated on Death or graft loss (p=0.007). First-year progression of maximal intimal thickness ≥0.5 mm after heart transplantation was associated with higher death or graft loss compared to <0.5 mm.
Synapse has enriched 10 related papers. Consider them for comparative context: